Gilead's Lurking Megablockbuster Drug

By Dave Williamson and Max Macaluso – Sep 11, 2013 at 10:45AM

NASDAQ: GILD

Gilead Sciences

Market Cap

$84B

Today's Change

(0.07%) $0.05

Current Price

$67.08

Price as of April 24, 2024, 4:00 p.m. ET

Sofosbuvir and the biotech's hepatitis-c pipeline have investors excited.

This episode of The Motley Fool's Market Checkup is dedicated to the world's largest pure play biotech stock, Gilead Sciences (GILD 0.07%) . Market Checkup gives a full examination of Gilead's second-quarter results, takes a closer look at the company's current product portfolio, and analyzes the future drugs that have investors excited about the stock's future.

In this video, health care analysts David Williamson and Max Macaluso drill down on Gilead's strong drug development pipeline. Watch and find out why investors should be excited about Gilead's diversification into hepatitis-C treatments and why a drug currently under FDA review is poised to become a megablockbuster.

Follow David on Twitter: @MotleyDavid.

David Williamson owns shares of Johnson & Johnson and Merck. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D. owns shares of Gilead Sciences.

The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.